

Modification Form for Permit BIO-UWO-0165

Permit Holder: Bryan Neff

PLEASE ATTACH A MATERIAL SAFETY DATA SHEET OR EQUIVALENT FOR NEW BIOLOGICAL AGENTS. *(None available)*
 PLEASE ATTACH A BRIEF DESCRIPTION OF THE WORK THAT EXPLAINS THE BIOLOGICAL AGENTS USED AND HOW THEY WILL BE STORED, USED AND DISPOSED OF. *(Attached)*

Approved Personnel

(Please stroke out any personnel to be removed)

- Tim Hain
- Jessica Van Zwol
- Chandra Rodgers
- Ross Breckels
- Shawn Garner

Additional Personnel

(Please list additional personnel here)

Aimee Lee Houde, Department of Biology

	Please stroke out any approved Biological Agent(s) to be removed	Write additional Biological Agent(s) for approval below. Give the full name
Approved Microorganisms	E. coli DH5alpha	<i>Paenibacillus thiaminolyticus</i>
Approved Primary and Established Cells		
Approved Use of Human Source Material		
Approved Genetic Modifications (Plasmids/Vectors)	[Plasmid] P-Gem T Easy.	
Approved Use of Animals	Salmon, Bluegill sunfish, guppy fish	
Approved Biological Toxin(s)		

Approved Gene
Therapy

--	--

Approved Plants and
Insects

--	--

As the Principal Investigator, I have ensured that this project will follow the Western Biosafety Guidelines and Procedures Manual for Containment Level 1 2 Laboratories (and the Level 3 Facilities Manual for Level 3 projects). I will ensure that UWO faculty, staff and students working in my laboratory have an up-to-date Hazard Communication Form, found at <http://www.shs.uwo.ca/workplace/newposition.htm>

Signature of Permit Holder:



Current Classification: 1

Containment Level for Added Biohazards: 1

Date of Last Biohazardous Agents Registry Form: May 14, 2010

Date of Last Modification (if applicable): _____

BioSafety Officer(s)*: _____

*For work being performed at Institutions affiliated with Western University, the Safety Officer for the Institution where experiments will take place must sign the form prior to its being sent to Western University Biosafety Officer.

Chair, Biohazards Subcommittee:

Date:

Description of Work:

Rationale:

Atlantic salmon were once abundant in Lake Ontario but were extinct by 1900. One issue that may be impeding the restoration of Atlantic salmon in Lake Ontario is thiamine deficiency as a result of adult Atlantic salmon feeding on prey fishes that contain high levels of thiaminase (produced by *Paenibacillus thiaminolyticus*), an enzyme that breaks down the vitamin thiamine. Three populations of Atlantic salmon are being considered for reintroduction efforts into Lake Ontario comprising of LaHave River, Lac St. Jean, and Sebago Lake. It is unknown whether these candidate strains of Atlantic salmon have genetic adaptations to coping with diets high in thiaminase.

I would like to feed Atlantic salmon experimental diets low and high in thiaminase at the MNR Codrington Facility, Codrington, Ontario up to three years. Since Codrington does not have the capacity for water treatment, Environment Canada would like me to determine if the bacteria remains alive in water or feces, and if yes, how much of the bacteria remains alive at the Fish Research Hatchery in the Duckhouse, where the water can be treated. This information would be required for an Environment Canada substance notification assessment.

Methods:

Manufactured feed (Dominique Bureau, Fish Nutrition lab, University of Guelph) will be mixed with bacterial thiaminase isolated from alewife gut contents (imported from Dale Honeyfield, Northern Appalachian Research Laboratory, Wellsboro, Pennsylvania) to become high thiaminase feed. Feed will be stored in a -20°C freezer until used. Ten rainbow trout will be kept in a circular tank with 100% recirculation in the Fish Research Hatchery in the Duckhouse. Rainbow trout (as a model of Atlantic salmon) will be fed once a day the high thiaminase feed for one week.

I will examine water and fecal samples for thiaminase bacteria using a plate overlay of thiamine and peroxidase (Abe et al. 1986). If the thiamine is degraded, the bacteria should be present and I can validate and quantify the bacteria using gram staining and light microscopy (Nakamura 1990). At the end of the experiment, there will be a planned decontamination using 200 ppm chlorine for 12 hours. Water samples will then be checked for the bacteria and the absence of bacteria will be confirmed before being released to the municipal drain.

References:

- Abe M, Nishimune T, Ito S, Kimoto M, Hayashi R. 1986. A simple method for the detection of two types of thiaminase-producing colonies. *FEMS Microbiology Letters* 34: 129-133.
- Nakamura LK. 1990. *Bacillus thiaminolyticus* sp. nov., nom. rev. *International Journal of Systematic Bacteriology* 40: 242-246.

Intended start August 1, 2012

Subject: Fw: thiaminase bacteria from US

To: ahoude@uwo.ca

Date: 05/23/12 01:50 PM

From: Permit-Permis <permitpermis@phac-aspc.gc.ca>

Dear Aimee Lee Houde,

Thanks for your questions.

Paenibacillus thiaminolyticus is a risk group 1 human pathogen, an Import Permit is not required from PHAC.

Kind Regards

Josee Davies

Regulatory Technologist / Technologiste en réglementation
Public Health Agency of Canada / Agence de santé publique du Canada
Pathogen Regulation Directorate / Direction de la réglementation des
agents pathogènes
100 ch. Colonnade Rd. AL: 6201A Ottawa, Ontario, Canada, K1A 0K9
Tel: (613) 957-1779/ Fax: (613)941-0596
<http://www.phac-aspc.gc.ca/lab-bio/index-eng.php>

The Pathogen Regulation Directorate turnaround time from receipt of a complete application or checklist to permit or compliance letter is on the order of 20 business days.

As part of the Public Health Agency of Canada's contribution to the Federal Sustainable Development Strategy, in compliance with the Federal Sustainable Development Act, please note that as of May 21st, 2012, all documents will be sent by fax ONLY and paper copies will no longer be mailed.

La Direction de la réglementation des agents pathogènes a un délai d'attente depuis la réception d'une demande complète jusqu'à l'émission du document approprié de 20 jours ouvrables.

Dans le cadre de la Stratégie ministérielle de développement durable de l'Agence de la santé publique du Canada et en accord avec la Loi fédérale sur le développement durable, veuillez noter que dès le 21 mai 2012, tous les documents seront envoyés par télécopieur SEULEMENT, les copies papier ne seront plus envoyées par la poste.

----- Forwarded by Permit-Permis/HC-SC/GC/CA on 2012-05-23 01:34 PM -----

----- Forwarded by Isabelle Robert/HC-SC/GC/CA on 2012-05-23 10:34 AM -----

thiaminase bacteria from US

Aimee Lee Houde

to:

biosafety.biosecurite

2012-05-23 09:59 AM

From:

Aimee Lee Houde <ahoude@uwo.ca>

Subject: **Re: thiaminase bacteria from US**
To: Aimee Lee Houde <ahoude@uwo.ca>

Date: 05/23/12 09:07 AM
From: ImportZoopath <importzoopath@inspection.gc.ca>

ImportZoopath.vcf (186bytes)

Dear Ms. Lee Houde,

We have performed a short risk assessment. This organism will be classified as level 1, as it is indirectly related to disease in animals. It is not pathogenic itself. Therefore, you will not require an import permit from our section. Please note that other regulations may apply, such as PHAC Human Pathogen Importation Regulation. You may wish to contact this agency for inquiry.

If you have any question, do not hesitate to contact our office.

Regards,

Cynthia Labrie

Office of Biohazard Containment & Safety, CFIA | Bureau du
confinement des biorisques et de la sécurité, ACIA
Government of Canada | Gouvernement du Canada
1400 Merivale, Ottawa ON K1A0Y9
Phone/Tél.: (613) 773-6520
Fax/ Téléc.: (613) 773-6521
ImportZoopath@inspection.gc.ca

Please visit our website
<http://www.inspection.gc.ca/english/sci/bio/bioe.shtml> / Veuillez
visiter notre site internet
<http://www.inspection.gc.ca/francais/sci/bio/biof.shtml>

CONFIDENTIALITY NOTICE -This message and any attachments are for the sole use of the intended recipient(s) and may contain privileged and confidential information. Any unauthorized review, use, disclosure or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender immediately and destroy the message. Thank you.

AVIS DE CONFIDENTIALITÉ :Ce message et tous attachements s'adressent seulement au(x) destinataire(s) visé(s) et peuvent contenir de l'information confidentielle ou protégée. Toute lecture non autorisée, utilisation, divulgation ou distribution est strictement interdite. Si vous n'êtes pas le destinataire visé, veuillez immédiatement en informer l'auteur et détruire le message. Merci.

>>> Aimee Lee Houde <ahoude@uwo.ca> 5/22/2012 10:44 am >>>
Hi Cynthia,

My name is Aimee Houde and I am a PhD student at Western University. I would like to import *Paenibacillus thiaminolyticus* from a research institution in Pennsylvania, USA. This bacteria is associated with thiaminase which induces thiamine deficiency in animals. I would be using the bacteria in a controlled diet experiment to examine whether there are genetic differences in thiaminase tolerance among three populations of Atlantic salmon that are being considered for reintroduction to Lake Ontario.

Subject: FW: PNC No. 313 - Draft Meeting Minutes

To: Aimee Lee Houde <ahoude@uwo.ca>

Cc: "Shahsavarani, Arash [NCR]" <Arash.Shahsavarani@ec.gc.ca>,
George Arvanitakis <George.Arvanitakis@hc-sc.gc.ca>

Date: 06/14/12 09:19 AM

From: "Dugal, Francois [NCR]" <Francois.Dugal@ec.gc.ca>

Hi Aimee:

Please find below some draft minutes from our meeting on June 8th. Please let me know if you have any additions or revisions to make!

Sorry for the delay.

Regards,

François

Minutes of PNC No. 313 Meeting

Friday, June 8, 2012

10:00 a.m. via Teleconference

Attendees:

Environment Canada

François Dugal

Arash Shahsavarani

Health Canada

George Arvanitakis

University of Western Ontario

Aimee Lee Houde

1. *Overview of proposed activity by the University of Western Ontario*

The living organism in question, *P. thiaminolyticus*, is implicated in producing an enzyme that breaks down thiamine. Through a controlled diet, the University of Western Ontario plans to administer the living organism to three populations of predatory fish. The activity is planned to be conducted at the Ontario Ministry of Natural Resources' Research Hatchery in Codrington. The flowthrough system currently in place at the facility would have releases directly into the nearby creek. However, the bacteria is said to be present in the diet administered to the fish only in trace amounts. About 300 fish are planned to be submitted to the experiment with 50% of them exposed to the bacterial feed.

Researchers at the University of Pennsylvania have isolated the bacteria and the University of Western Ontario would like to import a sample from them. The bacteria has originally been isolated from an area that would qualify as in the same ecozone as to where the experiment is planned to be conducted.

2. Containment and Notification under the NSNR(O)

The New Substances Notification Regulations (Organisms) [NSNR(O)] have an exemption from notification for R&D. Unless a living organism requires level 2, 3 or 4 containment as identified in the Laboratory Biosafety Guidelines, a living organism is exempt from notification under the NSNR(O) if it is manufactured or present in a contained facility in a quantity of less than 1 000 L and it is imported to a contained facility in a quantity that, at the time of the import, is less than 50 mL or 50 g. Knowing this, it was indicated that a sample of the living organism in question could be imported from the University of Pennsylvania so long as it was imported under conditions that met our exemption for Research and Development. However, a notification needs to be made to Environment Canada prior to the living organism being released into the environment. In the case of the proposed experiment, releases could occur from water being released into the creek, even though the bacteria are administered only in trace amounts.

3. Public Health Agency of Canada and Import Permits

Under the *Human Pathogen Importation Regulations* (HPIR), the Public Health Agency of Canada (PHAC) issues import permits for human pathogens. According to the HPIR, every person importing a human pathogen in Risk Group 2, 3 or 4, or toxin, as identified in the Laboratory Biosafety Guidelines, must obtain an import permit. Thus, an import permit is not required for a human pathogen in Risk Group 1 prior to import. However, an application may still need to be submitted to the PHAC (see: <http://www.phac-aspc.gc.ca/lab-bio/regul/reg-imp/h-patogen-importing-eng.php>). Therefore, Environment Canada will not require that an import permit be issued prior to the notification of a Risk Group 1 organism and neither would it require that an import permit be issued for a Risk Group 1 organism prior to its import or manufacture under R&D conditions. *See attached email from PHAC*

4. Next Steps

In order to assess whether a notification will be necessary for the proposed experiment, it was suggested that the living organism be imported from the University of Pennsylvania by the University of Western Ontario under R&D conditions and that a preliminary experiment be conducted in a closed system in order to determine how much of the living organism can be detected in the effluent and, therefore, to determine whether releases would occur. Furthermore, in the eventuality that a notification needs to be made to Environment Canada, the data generated from this experiment in a closed system would be useful in preparing the notification.

As such, the University of Western Ontario will:

- Follow-up with Environment Canada and Health Canada regarding how much of the living organism can be detected in waters that would be released in the Environment.
- Provide literature on previous work done with the living organism in question.

Environment Canada and Health Canada will:

- Provide minutes from our June 8th meeting.
- Provide guidance regarding whether an import permit from the Public Health agency of Canada is required for the living organism in question.
- Once information regarding quantities of the living organism proposed to be released is received, provide guidance on whether a notification is necessary regarding the proposed activity.

François Dugal
 Science and Technology Branch
 Program Development and Engagement Division
 Environment Canada
 200 Sacré-Cœur, 8th floor
 Gatineau QC K1A 0H3
Francois.dugal@ec.gc.ca
 Telephone 819-934-5989
 Government of Canada
 Website: www.ec.gc.ca

François Dugal

Direction générale des sciences et de la technologie
Division de la mobilisation et de l'élaboration de programmes
Environnement Canada

200 Sacré-Cœur, 8^e étage
Gatineau QC K1A 0H3

Francois.dugal@ec.gc.ca

Téléphone 819-934-5989

Gouvernement du Canada

Site Web: www.ec.gc.ca

**THE UNIVERSITY OF WESTERN ONTARIO
 BIOHAZARDOUS AGENTS REGISTRY FORM**
 Approved Biohazards Subcommittee: September 25, 2009
 Biosafety Website: www.uwo.ca/humanresources/biosafety/

This form must be completed by each Principal Investigator holding a grant administered by the University of Western Ontario or in charge of a laboratory/facility where the use of Level 1, 2 or 3 biohazardous agents is described in the laboratory or animal work proposed. The form must also be completed if any work is proposed involving animals carrying zoonotic agents infectious to humans or involving plants, fungi, or insects that require Public Health Agency of Canada (PHAC) or Canadian Food Inspection Agency (CFIA) permits.

This form must be updated at least every 3 years or when there are changes to the biohazards being used.

Containment Levels will be established in accordance with Laboratory Biosafety Guidelines, 3rd edition, 2004, Public Health Agency of Canada (PHAC) or Containment Standards for Veterinary Facilities, 1st edition 1996, Canadian Food Inspection Agency (CFIA).

Completed forms are to be returned to Occupational Health and Safety, (OHS), (Support Services Building, Room 4190) for distribution to the Biohazard Subcommittee. For questions regarding this form, please contact the Biosafety Officer at extension 81135 or biosafety@uwo.ca. If there are changes to the information on this form (excluding grant title and funding agencies), contact Occupational Health and Safety for a modification form. See website: www.uwo.ca/humanresources/biosafety/

PRINCIPAL INVESTIGATOR	Bryan Neff
SIGNATURE	
DEPARTMENT	Biology
ADDRESS	204 Collip Building, UWO
PHONE NUMBER	519-850-2532
EMERGENCY PHONE NUMBER(S)	519-652-6844
EMAIL	bneff@uwo.ca

Location of experimental work to be carried out: Building(s) BGS Room(s) 3056, 3054

*For work being performed at Institutions affiliated with the University of Western Ontario, the Safety Officer for the Institution where experiments will take place must sign the form prior to its being sent to the University of Western Ontario Biosafety Officer (See Section 12.0, Approvals).

FUNDING AGENCY/AGENCIES: NSERC
 GRANT TITLE(S): Molecular and Behavioural Ecology of Fishes

PLEASE ATTACH A BRIEF DESCRIPTION OF YOUR WORK THAT EXPLAINS THE BIOHAZARDS USED AND HOW THEY WILL BE USED. PROJECTS SUBMITTED WITHOUT A SUMMARY WILL NOT BE REVIEWED. A GRANT SUMMARY PAGE MAYBE ADEQUATE IF IT PROVIDES SUFFICIENT DETAIL ABOUT EACH BIOHAZARD USED.

Names of all personnel working under Principal Investigators supervision in this location:

<u>Shawn Garner</u>	<u>Jessica Van Zwol</u>
<u>Tim Hain</u>	
<u>Scott Colborne</u>	
<u>Ross Breckels</u>	
<u>Chandra Rodgers</u>	

1.0 Microorganisms

1.1 Does your work involve the use of biological agents? YES NO
 (including but not limited to bacteria and other microorganisms, viruses, prions, parasites or pathogens of plant or animal origin)? If no, please proceed to Section 2.0

Do you use microorganisms that require a permit from the CFIA? YES NO

If YES, please give the name of the species. _____

What is the origin of the microorganism(s)? _____

Please describe the risk (if any) of escape and how this will be mitigated:

Please attach the CFIA permit.

Please describe any CFIA permit conditions:

1.2 Please complete the table below:

Name of Biological agent(s)*	Is it known to be a human pathogen? YES/NO	Is it known to be an animal pathogen? YES/NO	Is it known to be a zoonotic agent? YES/NO	Maximum quantity to be cultured at one time? (in Litres)	Source/Supplier	PHAC or CFIA Containment Level
E. coli DH5 α	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input type="radio"/> Yes <input checked="" type="radio"/> No	0.01	Invitrogen	<input checked="" type="radio"/> 1 <input type="radio"/> 2 <input type="radio"/> 3
	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> Yes <input type="radio"/> No			<input type="radio"/> 1 <input type="radio"/> 2 <input type="radio"/> 3
	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> Yes <input type="radio"/> No			<input type="radio"/> 1 <input type="radio"/> 2 <input type="radio"/> 3
	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> Yes <input type="radio"/> No			<input type="radio"/> 1 <input type="radio"/> 2 <input type="radio"/> 3

*Please attach a Material Safety Data Sheet or equivalent from the supplier.

2.0 Cell Culture

2.1 Does your work involve the use of cell cultures? YES NO

If no, please proceed to Section 3.0

2.2 Please indicate the type of primary cells (i.e. derived from fresh tissue) that will be grown in culture:

Cell Type	Is this cell type used in your work?	Source of Primary Cell Culture Tissue	AUS Protocol Number
Human	<input type="radio"/> Yes <input type="radio"/> No		Not applicable
Rodent	<input type="radio"/> Yes <input type="radio"/> No		
Non-human primate	<input type="radio"/> Yes <input type="radio"/> No		
Other (specify)	<input type="radio"/> Yes <input type="radio"/> No		

2.3 Please indicate the type of established cells that will be grown in culture in:

Cell Type	Is this cell type used in your work?	Specific cell line(s)*	Supplier / Source
Human	<input type="radio"/> Yes <input type="radio"/> No		
Rodent	<input type="radio"/> Yes <input type="radio"/> No		
Non-human primate	<input type="radio"/> Yes <input type="radio"/> No		
Other (specify)	<input type="radio"/> Yes <input type="radio"/> No		

*Please attach a Material Safety Data Sheet or equivalent from the supplier. (For more information, see www.atcc.org)

2.4 For above named cell types(s) indicate PHAC or CFIA containment level required 1 2 3

3.0 Use of Human Source Materials

3.1 Does your work involve the use of human source materials? YES NO

If no, please proceed to Section 4.0

3.2 Indicate in the table below the Human Source Material to be used.

Human Source Material	Source/Supplier /Company Name	Is Human Source Material Infected With An Infectious Agent? YES/NO	Name of Infectious Agent (If applicable)	PHAC or CFIA Containment Level (Select one)
Human Blood (whole) or other Body Fluid		<input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unknown		<input type="radio"/> 1 <input type="radio"/> 2 <input type="radio"/> 3
Human Blood (fraction) or other Body Fluid		<input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unknown		<input type="radio"/> 1 <input type="radio"/> 2 <input type="radio"/> 3
Human Organs or Tissues (unpreserved)		<input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unknown		<input type="radio"/> 1 <input type="radio"/> 2 <input type="radio"/> 3
Human Organs or Tissues (preserved)		Not Applicable		Not Applicable

4.0 Genetically Modified Organisms and Cell lines

4.1 Will genetic modifications be made to the microorganisms, biological agents, or cells described in Sections 1.0 and 2.0? YES NO If no, please proceed to Section 5.0

4.2 Will genetic modification(s) involving plasmids be done? YES, complete table below NO

Bacteria Used for Cloning *	Plasmid(s) *	Source of Plasmid	Gene Transfected	Describe the change that results
E. coli DH5 α	P-Gem T Easy	Promega	MHC	Not expressed, no change to bacteria

* Please attach a Material Data Sheet or equivalent if available.

Per OSHA 29CFR1910.1200, Part IV of the Controlled Products Regulations (CPR) of Canada, this product does not require a Material Safety Data Sheet.
(<http://www.promega.com/msds/nhlusa.htm>)

* DESCRIPTION MUST BE ATTACHED TO THIS FORM OR PROJECT WILL NOT BE REVIEWED*

4.3 Will genetic modification(s) involving viral vectors be made? YES, complete table below NO

Virus Used for Vector Construction	Vector(s) *	Source of Vector	Gene(s) Transduced	Describe the change that results

* Please attach a Material Safety Data Sheet or equivalent.

4.4 Will genetic sequences from the following be involved?

- ◆ HIV YES, please specify _____ NO
- ◆ HTLV 1 or 2 or genes from any Level 1 or Level 2 pathogens YES, specify _____ NO
- ◆ SV 40 Large T antigen YES NO
- ◆ E1A oncogene YES NO
- ◆ Known oncogenes YES, please specify _____ NO
- ◆ Other human or animal pathogen and or their toxins YES, please specify _____ NO

- 4.5 Will virus be replication defective? YES NO
- 4.6 Will virus be infectious to humans or animals? YES NO
- 4.7 Will this be expected to increase the containment level required? YES NO
- No viruses will be used

5.0 Human Gene Therapy Trials

5.1 Will human clinical trials be conducted involving a biological agent? YES NO
 (including but not limited to microorganisms, viruses, prions, parasites or pathogens of plant or animal origin)
 If no, please proceed to Section 6.0

5.2 If YES, please specify which biological agent will be used: _____
 Please attach a full description of the biological agent.

5.2 Will the biological agent be able to replicate in the host? YES NO

5.3 How will the biological agent be administered? _____

5.4 Please give the Health Care Facility where the clinical trial will be conducted: _____

5.5 Has human ethics approval been obtained? YES, number: _____ NO PENDING

6.0 Animal Experiments

6.1 Will live animals be used? YES NO If no, please proceed to section 7.0

6.2 Name of animal species to be used salmon, bluegill sunfish, guppies

6.3 AUS protocol # 2006-062 Neff

6.4 Will any of the agents listed in section 4.0 be used in live animals YES, specify: _____ NO

6.5 Will the agent(s) be shed by the animal: YES NO, please justify:
Animals not exposed to agents

13.0 Containment Levels

11.1 For the work described in sections 1.0 to 9.0, please indicate the highest HC or CFIA Containment Level required. 1 2 3

13.2 Has the facility been certified by OHS for this level of containment?
 YES, permit # if on-campus _____
 NO, please certify _____
 NOT REQUIRED for Level 1 containment

14.0 Procedures to be Followed

14.1 As the Principal Investigator, I will ensure that this project will follow the Western Biosafety Guidelines and Procedures Manual for Containment Level 1 & 2 Laboratories (and the Level 3 Facilities Manual for Level 3 projects). I will ensure that UWO faculty, staff and students working in my laboratory have an up-to-date Hazard Communication Form, found at <http://www.wph.uwo.ca/>

SIGNATURE  Date: April 13, 2010

14.2 Please describe additional risk reduction measures will be taken beyond containment level 1, 2, or 3 measures, that are unique to this agent.
No special containment needed

14.3 Please outline what will be done if there is an exposure to the biohazards listed, such as a needlestick injury:
None of the biohazards listed are human pathogens

15.0 Approvals

UWO Biohazard Subcommittee: SIGNATURE: 
Date: 14 May 2010

Safety Officer for Institution where experiments will take place: SIGNATURE: _____
Date: _____

Safety Officer for University of Western Ontario (if different from above): SIGNATURE: 
Date: May 14, 2010

Approval Number: BIO-uwo-0165 Expiry Date (3 years from Approval): May 13, 2013

Special Conditions of Approval:

Research summary - Evolutionary and Ecological Functional Genomics

The genomic era has ushered in a new multiple disciplinary area of research called evolutionary and ecological functional genomics. This research focuses on the genes that affect ecological success and evolutionary (DARWINIAN) fitness in populations living in their natural environments. At the root of this discipline is the use of genomic tools such as MICROSATELLITES for mapping quantitative traits, MICROARRAYS for quantifying gene expression profile in the transcriptome, and MUTAGENESIS and RNAi for gene knock-out and functional analysis. These tools can now be applied to ecological and evolutionary model systems, and this application is a significant advancement because an individual's phenotype is determined by the interaction of genes and environment (G×E). Thus to understand the natural function of genes, they must be studied in their natural environment.

My lab and collaborators are conducting research on the evolutionary and ecological functional genomics of three fishes comprising bluegill, guppy and Chinook salmon. In bluegill, we are targeting genes involved in mediating the alternative male life histories, kin recognition, parental care, and foraging polymorphisms. In the guppy, we are examining immunity genes including those of the MAJOR HISTOCOMPATIBILITY COMPLEX, and genes involved in the alternative mating tactics (courting and sneaking). In Chinook salmon, we are examining genes involved in migration time, precocious maturation, and immunity. Some of this work will involve MICROARRAYS, but we also use CLONING to assess the genetic variation present in individuals and populations.

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Product code 18265017
Product name Subcloning Efficiency™ DH5alpha™ Competent Cells

Company/Undertaking Identification

INVITROGEN CORPORATON
5791 VAN ALLEN WAY
PO BOX 6482
CARLSBAD, CA 92008
760-603-7200

INVITROGEN CORPORATION
5250 MAINWAY DRIVE
BURLINGTON, ONT
CANADA L7L 6A4
800-263-6236

GIBCO PRODUCTS
INVITROGEN CORPORATION
3175 STALEY ROAD P.O. BOX 68
GRAND ISLAND, NY 14072
716-774-6700

24 hour Emergency Response (Transport): 866-536-0631
301-431-8585
Outside of the U.S. ++1-301-431-8585

For research use only

2. COMPOSITION/INFORMATION ON INGREDIENTS**Hazardous/Non-hazardous Components**

The product contains no substances which at their given concentration, are considered to be hazardous to health. We recommend handling all chemicals with caution.

3. HAZARDS IDENTIFICATION**Emergency Overview**

The product contains no substances which at their given concentration, are considered to be hazardous to health

3. HAZARDS IDENTIFICATION

Form
Liquid

Principle Routes of Exposure/

Potential Health effects

Eyes	No information available
Skin	No information available
Inhalation	No information available
Ingestion	May be harmful if swallowed.

Specific effects

Carcinogenic effects	No information available
Mutagenic effects	No information available
Reproductive toxicity	No information available
Sensitization	No information available

Target Organ Effects

No information available

HMIS

Health	0
Flammability	0
Reactivity	0

4. FIRST AID MEASURES

Skin contact	Wash off immediately with plenty of water. If symptoms persist, call a physician.
Eye contact	Rinse thoroughly with plenty of water, also under the eyelids. If symptoms persist, call a physician.
Ingestion	Never give anything by mouth to an unconscious person. If symptoms persist, call a physician.
Inhalation	Move to fresh air. If symptoms persist, call a physician.
Notes to physician	Treat symptomatically.

5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	Dry chemical
Special protective equipment for firefighters	Wear self-contained breathing apparatus and protective suit

6. ACCIDENTAL RELEASE MEASURES

Personal precautions	Use personal protective equipment
Methods for cleaning up	Soak up with inert absorbent material.

7. HANDLING AND STORAGE

Handling	No special handling advice required
Storage	Keep in properly labelled containers

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Occupational exposure controls

Exposure limits

Engineering measures Ensure adequate ventilation, especially in confined areas

Personal protective equipment

Respiratory Protection In case of insufficient ventilation wear suitable respiratory equipment

Hand protection

Protective gloves

Eye protection

Safety glasses with side-shields

Skin and body protection

Lightweight protective clothing.

Hygiene measures

Handle in accordance with good industrial hygiene and safety practice

Environmental exposure controls

Prevent product from entering drains.

9. PHYSICAL AND CHEMICAL PROPERTIES

General Information

Form

Liquid

Important Health Safety and Environmental Information

Boiling point/range °C No data available °F No data available

Melting point/range °C No data available °F No data available

Flash point °C No data available °F No data available

Autoignition temperature °C No data available °F No data available

Oxidizing properties No information available

Water solubility No data available

10. STABILITY AND REACTIVITY

Stability

Stable.

Materials to avoid

No information available

Hazardous decomposition products

No information available

Polymerization

Hazardous polymerisation does not occur.

11. TOXICOLOGICAL INFORMATION

Acute toxicity

Principle Routes of Exposure/

Potential Health effects

Eyes

No information available

Skin

No information available

Inhalation

No information available

Ingestion May be harmful if swallowed.

Specific effects

Carcinogenic effects
Mutagenic effects
Reproductive toxicity
Sensitization

(Long Term Effects)

No information available
No information available
No information available
No information available

Target Organ Effects

No information available

12. ECOLOGICAL INFORMATION

Ecotoxicity effects

No information available.

Mobility

No information available.

Biodegradation

Inherently biodegradable.

Bioaccumulation

Does not bioaccumulate.

13. DISPOSAL CONSIDERATIONS

Dispose of in accordance with local regulations

14. TRANSPORT INFORMATION

IATA

Proper shipping name

Not classified as dangerous in the meaning of transport regulations

Hazard Class

No information available

Subsidiary Class

No information available

Packing group

No information available

UN-No

No information available

15. REGULATORY INFORMATION

International Inventories

U.S. Federal Regulations

SARA 313

This product is not regulated by SARA.

Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)

This product does not contains HAPs.

U.S. State Regulations

California Proposition 65

This product does not contain chemicals listed under Proposition 65

WHMIS hazard class:

Non-controlled

This product has been classified according to the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR

16. OTHER INFORMATION

For research use only

The above information was acquired by diligent search and/or investigation and the recommendations are based on prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be used only as a guide. All materials and mixtures may present unknown hazards and should be used with caution. Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held liable for any damages or losses resulting from the handling or from contact with the product as described herein. THE INFORMATION IN THIS MSDS DOES NOT CONSTITUTE A WARRANTY, EXPRESSED OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.

End of Safety Data Sheet

